Sabina Gold & Silver Updates on Detail Engineering and Constructability Review Contracts for Proposed Goose Mine at Back River Gold Project in Nunavut, Canada

VANCOUVER, British Columbia, Nov. 12, 2020 (GLOBE NEWSWIRE) — Sabina Gold & Silver Corp (SBB.T/SGSVF.OTCQX), (“Sabina” or the “Company”) is pleased to report that the detail engineering contract has been awarded and work has commenced on the Goose Mine at its 100%-owned Back River Gold Project (“Back River” or the “Project”) in Nunavut, Canada.

After comprehensive evaluation of various construction delivery methods for the Process Plant at Goose, Sabina believes that a modified Engineering, Procurement, Construction Management (“EPCM”) method offers the greatest efficiency, flexibility and risk mitigation for development of the Goose Project.

This delivery model includes completion of detail engineering in a reimbursable cost model for engineering and procurement directly sourcing major process equipment, and pursuit of a fixed price construction bid.

Detail engineering will provide definitive material requirements per AACE class II standards (up to 70% project definition) and will result in development of procurement packages and delivery of issued for construction drawings. This approach de-risks the engineering aspect, better defines the execution plan and provides greater certainty of procurement and construction costs. With these details in hand, Sabina will solicit fixed price construction bids for the plant, including performance guarantees.


CONSULTANTS

Sabina has engaged Sacré-Davey Engineering Inc. (“SD”) to complete the detail engineering scope for the process plant and experienced Arctic builders, CGT Industrial (“CGT”) to review and evaluate the detailed design’s constructability and operability. The CGT team is also assisting in developing a construction execution plan.

SD has extensive experience ranging from feasibility studies and concepts to detailed design, system integration, and construction. They have executed projects across many industries, including mining, oil & gas, and forestry, among others.

CGT is a northern Arctic constructor with proven experience in the mining industry with a successful track record of involvement in projects that includes Pretivm’s Brucejack gold mine, Dominion Diamond’s Ekati and Diavik Diamond mines and Yukon Zinc’s Wolverine mine.

Both detailed engineering and the constructability and operations review have begun and are expected to be completed during Q1, 2021.

“We are pleased to be working with Sacre Davey and CGT on these initiatives,” said Bruce McLeod, President & CEO. “Both firms have significant experience which we believe aligns with Sabina’s approach to this Project. We also believe that given the global supply chain volatility due to the COVID-19 pandemic, this revised delivery approach bodes well for delivering more certainty around project costs and deliverables. We look forward to reporting further on our pre-development activities as they progress.”


OTHER KEY INITIATIVES

Sabina had selected FLSmidth (“FLS”) as the equipment manufacturer and FLS is actively working on their line-up of equipment and a definitive pricing model with a performance guarantee for the plant. FLS will also be engaged in commissioning support and critical spares management. This continued engagement with FLS will provide Sabina with more certainty for the phases of the Project throughout detailed engineering, commissioning, optimization, and training.

Sabina is also reaching out to power plant technology providers to support the design and development of construction drawings for a ~15MW power plant. Sabina expects this contract will be awarded before the end of the year.  

Sabina has engaged DT Engineering to design the Port Facility fuel farm and fuel distribution process. The objective is to receive, store and dispense 40 Million liters at the Port Facility area and at the Goose site.

Sabina consultants are also working on the design of various water diversion structures designed to mitigate seasonal flow, site wide road networks, waste dump designs and site wide water balance calculations.

In 2019 Sabina obtained a third-party logistics review for Project construction.  As part of the process, Sabina engaged various vessel operators to do a logistics review while finalizing plans for the material consolidation points for the Project, the Port Facility receiving schedule and offloading requirements. The inaugural winter ice road in 2018/19 provided the experience required to develop a robust logistics and procurement execution plan to support the Project’s material requirements.  The opportunity enabled Sabina to conduct winter ice road time studies and road management plans.  All these initiatives have been carried forward and will be incorporated into the updated Project execution plan. 


Sabina Gold & Silver Corp.

Sabina Gold & Silver Corp. is well-financed and is an emerging precious metals company with district scale, advanced, high grade gold assets in one of the world’s newest, politically stable mining jurisdictions: Nunavut, Canada.

Sabina released a Feasibility Study on its 100% owned Back River Gold Project which presents a project that has been designed on a fit-for purpose basis, with the potential to produce ~200,000 ounces a year for ~11 years with a rapid payback of 2.9 years (see “Technical Report for the Initial Project Feasibility Study on the Back River Gold Property, Nunavut, Canada” dated October 28, 2015).

The Project received its final Project Certificate on December 19, 2017. The Project received its Type A Water License on November 14, 2018 and its listing to enable deposition of tailings on Schedule 2 of the Metals and Diamond Mining Effluent Regulations on June 25, 2020. The Company is now in receipt of all major authorizations for construction and operations.

In addition to Back River, Sabina also owns a significant silver royalty on Glencore’s Hackett River Project. The silver royalty on Hackett River’s silver production is comprised of 22.5% of the first 190 million ounces produced and 12.5% of all silver produced thereafter.

For further information please contact:

Nicole Hoeller, Vice-President, Communications: 1 888 648-4218
[email protected]

Forward Looking Information

This news release contains “forward-looking information” within the meaning of applicable securities laws (the “forward-looking statements”), including our belief as to the extent, results and timing of and various studies relating to engineering studies, infrastructure improvement activities, exploration results and permitting and licensing outcomes. These forward-looking statements are made as of the date of this news release. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the future circumstances, outcomes or results anticipated in or implied by such forward-looking statements will occur or that plans, intentions or expectations upon which the forward-looking statements are based will occur. While we have based these forward-looking statements on our expectations about future events as at the date that such statements were prepared, the statements are not a guarantee that such future events will occur and are subject to risks, uncertainties, assumptions and other factors which could cause events or outcomes to differ materially from those expressed or implied by such forward-looking statements. Such factors and assumptions include, among others, the effects of general economic conditions, commodity prices, changing foreign exchange rates and actions by government and regulatory authorities and misjudgments in the course of preparing forward-looking statements. In addition, there are known and unknown risk factors which could cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Known risk factors include risks associated with exploration and project development; the need for additional financing; the calculation of mineral resources and reserves; operational risks associated with mining and mineral processing; fluctuations in metal prices; title matters; government regulation; obtaining and renewing necessary licenses and permits; environmental liability and insurance; reliance on key personnel; the potential for conflicts of interest among certain of our officers or directors; the absence of dividends; currency fluctuations; labour disputes; competition; dilution; the volatility of the our common share price and volume; future sales of shares by existing shareholders; and other risks and uncertainties, including those relating to the Back River Project and general risks associated with the mineral exploration and development industry described in our Annual Information Form, financial statements and MD&A for the fiscal period ended December 31, 2019 filed with the Canadian Securities Administrators and available at www.sedar.com. Although we have attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. We are under no obligation to update or alter any forward-looking statements except as required under applicable securities laws. This news release has been authorized by the undersigned on behalf of Sabina Gold & Silver Corp.

Bruce McLeod, President & CEO
Suite 1800 – Two Bentall Centre
555 Burrard Street
Vancouver, BC V7X 1M7
Tel 604 998-4175 Fax 604 998-1051
http://www.sabinagoldsilver.com

Sonatype and Fugue Partner to Shift Cloud Security Left and Ensure Continuous Policy Compliance

Innovative solution empowers developers to deliver secure applications and automatically help them configure secure and policy compliant cloud infrastructure

Fulton, MD and Frederick, MD, Nov. 12, 2020 (GLOBE NEWSWIRE) — Sonatype, the leading provider of innovation-friendly open source security tools, today announced a strategic partnership with Fugue, the company putting engineers in command of cloud security, to deliver the first infrastructure-as-code (IaC) solution that shifts cloud security left into the developer workflow. The partnership further advances the missions of Sonatype and Fugue to empower software developers with best-in-class tools so they can accelerate innovation and simultaneously improve application security, cloud infrastructure security, and continuous compliance with defined policy.

The combined capabilities of Sonatype and Fugue enable developers to find and fix security vulnerabilities when actively developing cloud applications, while at the same time preventing security vulnerabilities and compliance issues from surfacing in production due to misconfigured cloud infrastructure. The joint solution includes out-of-the-box guidance to assist developers when configuring IaC and automatically foster compliance with privacy and security standards, including CIS Foundations Benchmarks, GDPR, HIPAA, ISO 27001, NIST 800-53, PCI, SOC 2, and custom rules.   

“Sonatype has a long and successful history of providing front-line software developers with friendly feedback pertaining to the health of open source libraries, making it easy for them to identify and remediate security risk, without slowing down innovation,” said Wayne Jackson, CEO of Sonatype. “In today’s cloud-native world, developers are not just responsible for building secure applications, they’re also responsible for configuring and provisioning secure cloud infrastructure using tools like Terraform. By working with Fugue, we’re equipping developers with the right information at the right time so they can always make healthy decisions when configuring IaC.”

In Q1 2021, Sonatype will offer new Nexus IaC capabilities as an add-on to its Nexus Lifecycle product that incorporates Fugue’s cloud infrastructure security and compliance technology. This will make it possible for developers using Nexus Lifecycle to find and easily fix misconfigurations in Terraform plans before being applied to production infrastructure, and use those same policies with Fugue to ensure continuous compliance in production.  

For initial details, and to sign up to learn more about Sonatype’s Nexus Lifecycle IaC capabilities, go here. Additionally, Sonatype and Fugue will collaborate to bring the Fugue runtime SaaS continuous compliance solution to Sonatype customers, who can learn more here.

“Sonatype and Fugue have a strong history of leadership in empowering developers to securely build and operate in order to keep their data safe. We’re proud to partner with them to deliver a single solution to address the full breadth of cloud security and compliance challenges,” said Phillip Merrick, CEO of Fugue. “The mutable nature of cloud APIs brings serious risk of post-deployment misconfiguration, and Sonatype and Fugue are making it possible for the first time to address all relevant cloud vulnerability surfaces — from initial development to runtime production environments — with a single solution using the same policies.”  

Full Breadth Cloud Security and Compliance

Sonatype and Fugue are delivering a unified cloud security and compliance solution that empowers software developers to address the entire cloud threat landscape with:

  • Open-source governance with Sonatype’s Nexus platform to shift security of software applications left to address open source risk and known vulnerabilities automatically at every phase of the CI/CD pipeline.
  • Infrastructure-as-code governance with Sonatype’s new IaC capabilities, which integrate Fugue’s cloud infrastructure security and compliance technology for Terraform configurations.
  • Continuous cloud compliance with Fugue to ensure cloud environments remain in compliance and free of misconfiguration vulnerabilities post-deployment — and demonstrate it at all times with automated reporting. 

About Sonatype 

Sonatype is the leader in software supply chain automation technology with more than 350 employees, over 1,200 enterprise customers, and is trusted by more than 10 million software developers.  Sonatype’s Nexus platform enables DevOps teams and developers to automatically integrate security at every stage of the modern development pipeline by combining in-depth component intelligence with real-time remediation guidance. For more information, please visit Sonatype.com, or connect with us on Facebook, Twitter, or LinkedIn.

About Fugue

Fugue puts engineers in command of enterprise cloud security with tools to prove compliance, build security into cloud development, and stay safe by eliminating cloud misconfiguration. Fugue provides one-click reporting for CIS Foundations Benchmarks, GDPR, HIPAA, ISO 27001, NIST 800-53, PCI, and SOC 2. Customers such as AT&T, SAP NS2, and A+E Networks trust Fugue to protect their cloud environments. Fugue’s investors include New Enterprise Associates, Future Fund, and In-Q-Tel (IQT). Fugue is an AWS Advanced Technology Partner and Cloud Management Competency Partner and has twice been named a CyberSecurity Breakthrough Award winner. To learn more, visit www.fugue.co.

Elissa Walters
Sonatype
480-818-0734
[email protected]

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Golar LNG Limited – GLNG

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Golar LNG Limited (“Golar” or the “Company”) (NASDAQ: GLNG). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Golar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 



[Click here for information about joining the class action]

On September 24, 2020, media outlets reported that Eduardo Navarro Antonello, Chief Executive Officer of Golar’s joint-venture subsidiary Hygo Energy Transition Ltd., had been implicated in a bribery network investigated in connection with the ongoing Brazilian criminal investigation Operation Car Wash. 

On this news, Golar’s stock price fell $3.28 per share, or approximately 32%, to close at $6.86 per share on September 24, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

Sustainable Green Team, Ltd. (SGTM) Expands Its Mulch Contract with Circle K Convenient Stores, a Subsidiary of Alimentation Couche-Tard, Inc. (ANCUF)

ORLANDO, Fla., Nov. 12, 2020 (GLOBE NEWSWIRE) — Sustainable Green Team, Ltd. (OTC: SGTM) (“SGTM” or the “Company”), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, today announces that its wholly owned subsidiary Mulch Manufacturing, Inc. has expanded its 2021 mulch contracts with Circle K convenient stores, a subsidiary of Alimentation Couche-Tard, Inc. (OTC: ANCUF) (“ANCUF”). The original contract, finalized in October, has been increased to add an additional region to the initial three, bringing the total to four. The mulch contract expansion was obtained shortly after the Company reported another successful quarter, generating approximately $24.5 million in revenue and $5.5 million in gross profit within the nine months ending Sept. 30, 2020.

About Sustainable Green Team, Ltd. (SGTM)

Sustainable Green Team, Ltd. (“SGTM”), through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The Company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The Company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting tree debris through its tree services division and collection sites and then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The Company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and are positioned for rapid growth from the resulting synergistic opportunities identified. The Company’s customers include governmental, residential and commercial clients.

SGTM currently has two wholly owned subsidiaries to efficiently assess areas, recover, manufacture and distribute:

National Storm Recovery, LLC

National Storm Recovery, LLC (“NSR”) is composed of a team that has expertise in dangerous tree removal, debris hauling and debris management. The Company’s management team assesses storms by deploying its mobile command center to designated sites and then strategizing with its national partners, which include government agencies, prime contractors and subcontractors.

Central Florida Arborcare (“CFA”), a DBA of NSR, has spent more than 40 years perfecting its technique for proper tree care, removal and services. From tree removal, stump grinding and tree care to grapple hauling and storm recovery, CFA ensures properties remain safe and businesses can continue as usual.

To learn more please visit: https://www.centralfloridaarborcare.com

Mulch Manufacturing, Inc.

Mulch Manufacturing, Inc. (“MMI”), being vertically integrated, receives a large volume of wood fiber recovered from Central Florida Arborcare to feed raw material needs. MMI has the product line and distribution system to address a substantial customer base, which can be expanded.

To learn more please visit: https://mulchmfg.com

For additional information regarding SGTM’s operations, expansion plans and production facilities, view the Company’s presentation.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will” and other similar expressions, are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance or achievements to differ materially from anticipated results, performance or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise. No information in this press release should be construed in any matter whatsoever as an indication of the future performance of the Company’s revenues, financial condition or stock price.

Company Contact:

Anthony Raynor
CEO & Director
407.886.8733 Office

Corporate Communications:

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

Biotricity Launches Biocare Telemed for Safe and Convenient Remote Patient Care

Secure HIPAA compliant technology for at-risk chronic care patients

REDWOOD CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today introduced Biocare Telemed, a virtual clinic that provides user-friendly access for patients to receive outstanding medical care and remote patient cardiac monitoring from their physician of choice in the safety and comfort of their home.

“The arrival of COVID-19 has highlighted the importance of having remote care systems in place,” said Dr. Waqaas Al-Siddiq, founder & CEO, Biotricity Inc. “Biocare Telemed streamlines the process, allowing patients to skip the waiting room and receive excellent medical care when and where it’s needed without leaving the house.”

The Biocare Telemed platform is a complete solution for the clinic with the ability to book and manage appointments, connect diagnostic tools, and report, monitor and diagnose remotely using the Bioflux.

Traditional telemedicine provides consults for routine clinical needs as opposed to supporting the diagnostic and more complex needs of cardiac patients. With Biocare Telemed, clinicians can provide outstanding medical care to at-risk patients and those needing remote cardiac monitoring without leaving the safety of their home. The user-friendly platform helps ensure seamless integration into the clinics’ current workflow, saving time and reducing costs.

“Being able to provide my at-risk cardiac patients a HIPAA compliant telemedicine solution for virtual consults during COVID-19 has changed how I practice medicine,” said Dr. John Lassetter, President, Radial Heart First. “Biocare Telemed allows me to monitor and diagnose my patients from the safety of their homes. Telemedicine is here to stay as more and more patients are demanding virtual consults, and clinicians realize the benefits of it to their practices.”

Biotricity will initially offer the Biocare Telemed platform via limited release to selected physicians, followed by a broad rollout in Q4 2020.

For more information, visit www.biotricity.com.

About Biotricity, Inc.

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

MEDIA CONTACT
:

Donna Loughlin Michaels
LMGPR
408.393.5575
[email protected]

Important Cautions Regarding Forward-Looking
Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There cannot be any assurance that the Company will ever become profitable. During the three months ended June 30, 2020 the Company incurred a net loss attributable to common stockholders of $3.4 million. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

electroCore to Participate in Upcoming Virtual Investor Conferences

BASKING RIDGE, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Dan Goldberger, Chief Executive Officer, and Brian Posner, Chief Financial Officer, will participate in two upcoming investor conferences:

Sidoti Virtual Microcap Conference 2020

Format: corporate presentation followed by 1×1 virtual investor meetings
Date: Thursday, November 19
Time: 10:45am – 11:45am ET

Investors can register for the webcast HERE.

Canaccord Genuity Virtual MedTech & Diagnostics Forum

Format: 1×1 virtual investor meetings
Date: Thursday, November 19

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

Investors:

Hans Vitzthum
LifeSci Advisors
617-430-7578
[email protected]

or

Media Contact:

Jackie Dorsky
electroCore
973-290-0097
[email protected]

Leading Independent Proxy Firms ISS and Glass Lewis Recommend HC2 Stockholders Vote “FOR” Rights Offering Proposals

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — HC2 Holdings, Inc. (“HC2” or the “Company”) (NYSE:HCHC), a diversified holding company, announced today that leading independent proxy advisory firms Institutional Shareholder Services (“ISS”) and Glass Lewis have recommended, in connection with the Company’s current $65 million rights offering (the “Rights Offering”), that HC2 stockholders vote “FOR” both Proposals 1 and 2 at the Company’s Special Meeting of Stockholders to be held on November 20, 2020.

  • Proposal 1 – to increase the number of authorized shares of common stock from 80 million to 160 million (the “Authorized Shares Proposal”).
  • Proposal 2 – to approve the conversion of up to 35,000 shares of Series B preferred stock into common stock in connection with the Rights Offering.

Consummation of the Rights Offering is conditioned upon stockholder approval of the Authorized Shares Proposal. The Company believes that approval of both proposals will help ensure the successful completion of the Rights Offering, which will strengthen the Company’s balance sheet in advance of a potential refinancing of certain of its indebtedness.

HC2 expects to use the proceeds from the Rights Offering for general corporate purposes, including debt service and for working capital.

The Rights Offering will expire at 5:00 p.m., New York City time, on November 20, 2020, unless extended by the Company. The Company may extend the expiration date if stockholder approval of the Authorized Shares Proposal is not obtained on or prior to the previously scheduled expiration date. The Company reserves the right to amend or terminate the rights offering at any time prior to its expiration date.

A copy of the prospectus and prospectus supplement for the rights offering is available to stockholders on the Company’s website and at the website maintained by the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov. Holders of shares of common stock in “street name” through a brokerage account, bank or other nominee will not receive physical rights certificates and must instruct their broker, bank or nominee whether to exercise subscription rights on their behalf. For any questions or further information about the rights offering, please call Okapi Partners LLC, the information agent for the Rights Offering, at (855) 208-8902 (toll-free).

Neither the Company nor its Board of Directors has, or will, make any recommendation to stockholders regarding the exercise or sale of rights in the Rights Offering. Stockholders should make an independent investment decision about whether or not to exercise or sell their rights based on their own assessment of the Company’s business and the Rights Offering.

The
R
ights
O
ffering
is being made
pursuant to HC2’s effective shelf registration statement on Form S-3, filed with the SEC on September 9, 2020, and a prospectus supplement containing the detailed terms of the
R
ights
O
ffering
filed with the SEC on October 7, 2020. The information in this press release is not complete and is subject to change. This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities, nor shall there be any offer, solicitation or sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful under the securities laws of such state or jurisdiction. The
R
ights
Offering
is being
made only by means of a prospectus and a related prospectus supplement, copies of which
have been
distributed to all eligible stockholders and may also be obtained free of charge at the website maintained by the SEC at www.sec.gov or by contacting the information agent for the rights offering.

About HC2

HC2 Holdings, Inc. is a publicly traded (NYSE:HCHC) diversified holding company, which seeks opportunities to acquire and grow businesses that can generate long-term sustainable free cash flow and attractive returns in order to maximize value for all stakeholders. HC2 has a diverse array of operating subsidiaries across multiple reportable segments, including Infrastructure, Clean Energy, Life Sciences, Spectrum, Insurance and Other. HC2’s largest operating subsidiary is DBM Global Inc., a family of companies providing fully integrated structural and steel construction services. Founded in 1994, HC2 is headquartered in New York, New York.

C
autionary Statement Regarding Forward-Looking Statemen
ts

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains, and certain oral statements made by our representatives from time to time may contain, forward-looking statements, including, among others, statements regarding the Rights Offering, including, among others, expected timing, the use of proceeds from the Rights Offering, the size of the Rights Offering and other terms of the Rights Offering, all of which involve risks, assumptions and uncertainties, many of which are outside of the Company’s control, and are subject to change. The consummation of the Rights Offering is also subject to certain conditions, including stockholder approval of the Authorized Shares Proposal and market conditions. Accordingly, no assurance can be given that the Rights Offering will be consummated on the terms described above or at all. All forward-looking statements speak only as of the date made, and unless legally required, HC2 undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Investor Relations
[email protected]
(212) 235-2691

Harmony Biosciences Reports Third Quarter 2020 Financial Results and Business Updates

WAKIX
®
(pitolisant)
Total
Revenue
of $45.6 Million for Third Quarter of 2020

Differentiated Product Profile Aligns with Unmet Medical Need

On
Track to Initiate Phase 2 Trial in
Patients with
Prader-Willi Syndrome by Year End

Conference
C
all and
W
ebcast to be held today at 
8
:30
a
.m. Eastern Time

PLYMOUTH MEETING, Penn. and CHICAGO, Nov. 12, 2020 (GLOBE NEWSWIRE) — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today reported financial results for the quarter ended September 30, 2020, and provided recent business updates.

“Harmony experienced another productive quarter with continued WAKIX revenue growth and meaningful advancement of our key clinical programs,” commented John C. Jacobs, Harmony’s President and Chief Executive Officer. “WAKIX sales continued to increase on a quarterly basis through the COVID-19 pandemic, reflecting the unmet medical need for a first-in-class medication with a novel mechanism of action. The recent approval of the cataplexy indication for WAKIX expanded the label in narcolepsy which, along with WAKIX being the only FDA approved product for narcolepsy that is not scheduled as a controlled substance, provides additional commercial opportunity. With a robust cash position stemming from our recent IPO, we have the financial resources to continue supporting our commercialization efforts for WAKIX, advance our clinical programs, and to pursue the acquisition of additional assets that would be complimentary to our existing commercial footprint and core areas of expertise.”

Third Quarter 2020 Financial Highlights:

  • Net product revenue was $45.6 million for the third quarter ended September 30, 2020.
  • Research and development expenses were $4.2 million for the third quarter of 2020 compared with $4.3 million for the third quarter of 2019.
  • Sales and marketing expenses were $12.6 million for the third quarter of 2020 compared with $12.9 million for the third quarter of 2019.
  • General and administrative expenses were $10.5 million for the third quarter of 2020 compared with $12.6 million for the third quarter of 2019.
  • Net income was $1.9 million for the third quarter of 2020 compared with a net loss of $31.9 million for the third quarter of 2019.
  • Cash and cash equivalents as of September 30, 2020 was $221.7 million.

Harmony Founder and Chairman, and Paragon Biosciences Chairman and CEO, Jeff Aronin, commented, “From the time we founded Harmony, to its FDA approval of WAKIX, and recent approval of a second indication, the team has worked relentlessly to build a company that has contributed to scientific innovation in neurological disorders. We are pleased with Harmony’s continued progress to address unmet medical needs, including the benefits that WAKIX has provided for people living with narcolepsy.”  

Recent Program Highlights and Updates:

WAKIX® (pitolisant) in Narcolepsy

  • On October 13, 2020, the U.S. Food and Drug Administration (FDA) approved WAKIX for the treatment of cataplexy in adult patients with narcolepsy. This approval expands the label for WAKIX and broadens its clinical utility for healthcare professionals managing adult patients living with narcolepsy. WAKIX is the first and only treatment approved by the FDA for people with excessive daytime sleepiness (EDS) or cataplexy associated with narcolepsy that is not scheduled as a controlled substance by the U.S. Drug Enforcement Administration (DEA).

Pitolisant in Patients with Prader-Willi Syndrome (PWS) and Myotonic Dystrophy (DM)

  • PWS and DM are rare, genetic multi-system diseases for which there are no approved treatments for many of the symptoms, resulting in significant unmet medical needs.
    • For PWS, clinical sites are being activated to conduct a Phase 2 randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of pitolisant in patients with PWS, with the primary endpoint being EDS. We are on-track to initiate this trial this year.
    • For DM, we are on-track to submit an IND by year end with the plan to initiate a Phase 2 clinical trial in the first half of 2021.

Recent Business Updates:

  • On August 21, 2020 we successfully completed our upsized IPO of 6,151,162 shares of common stock at a public offering price of $24.00 per share, including an exercise in full of the underwriters’ option to purchase additional shares. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $147.6 million.
  • In November, we expanded the depth and breadth of our Board of Directors with the addition of Mark Graf and Eric Motley.

Conference Call
Today at 8:30 a.m. ET

We are hosting our third quarter 2020 financial results conference call and webcast today beginning at 8:30 a.m. Eastern Time. The live and replayed webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. To participate in the live call by phone, dial (833) 614-1471 (domestic) or +1 (914) 987-7209 (international), and reference passcode 7489154. A replay will be accessible until November 19, 2020 by dialing (855) 859-2056 (domestic) or +1 (404) 537-3406 (international).

About WAKIX® (pitolisant) Tablets

WAKIX, a first-in-class medication, is approved by the U.S. Food and Drug Administration for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy and has been commercially available in the U.S. since Q4 2019. It was granted orphan drug designation for the treatment of narcolepsy in 2010. WAKIX is a selective histamine 3 (H₃) receptor antagonist/inverse agonist. Although, the mechanism of action of WAKIX is unclear, its efficacy could be mediated through its activity at H₃ receptors, thereby increasing the synthesis and release of histamine, a wake promoting neurotransmitter. WAKIX was designed and developed by Bioprojet Société Civile de Recherche (Bioprojet). Harmony has an exclusive license from Bioprojet to develop, manufacture and commercialize pitolisant in the United States.


Indications and Usage


WAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy.


Important Safety Information

Contraindications

WAKIX is contraindicated in patients with known hypersensitivity to pitolisant or any component of the formulation. Anaphylaxis has been reported. WAKIX is also contraindicated in patients with severe hepatic impairment.

Warnings and Precautions

WAKIX prolongs the QT interval; avoid use of WAKIX in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval. Avoid use in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval. 

The risk of QT prolongation may be greater in patients with hepatic or renal impairment due to higher concentrations of pitolisant; monitor these patients for increased QTc. Dosage modification is recommended in patients with moderate hepatic impairment and moderate or severe renal impairment (see full prescribing information). WAKIX is not recommended in patients with end-stage renal disease (ESRD).

Adverse Reactions

In the placebo-controlled clinical trials conducted in patients with narcolepsy with or without cataplexy, the most common adverse reactions (≥5% and twice placebo) for WAKIX were insomnia (6%), nausea (6%), and anxiety (5%). Other adverse reactions that occurred at ≥2% and more frequently than in patients treated with placebo included headache, upper respiratory infection, musculoskeletal pain, heart rate increased, hallucinations, irritability, abdominal pain, sleep disturbance, decreased appetite, cataplexy, dry mouth, and rash.

Drug Interactions

Concomitant administration of WAKIX with strong CYP2D6 inhibitors increases pitolisant exposure by 2.2-fold. Reduce the dose of WAKIX by half. 

Concomitant use of WAKIX with strong CYP3A4 inducers decreases exposure of pitolisant by 50%. Dosage adjustments may be required (see full prescribing information). 

H1 receptor antagonists that cross the blood-brain barrier may reduce the effectiveness of WAKIX. Patients should avoid centrally acting H1 receptor antagonists. 

WAKIX is a borderline/weak inducer of CYP3A4. Therefore, reduced effectiveness of sensitive CYP3A4 substrates may occur when used concomitantly with WAKIX. The effectiveness of hormonal contraceptives may be reduced when used with WAKIX and effectiveness may be reduced for 21 days after discontinuation of therapy.

Use in Specific Populations

WAKIX may reduce the effectiveness of hormonal contraceptives. Patients using hormonal contraception should be advised to use an alternative non-hormonal contraceptive method during treatment with WAKIX and for at least 21 days after discontinuing treatment. 

There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to WAKIX during pregnancy. Patients should be encouraged to enroll in the WAKIX pregnancy registry if they become pregnant. To enroll or obtain information from the registry, patients can call 1-800-833-7460.

The safety and effectiveness of WAKIX have not been established in patients less than 18 years of age. 

WAKIX is extensively metabolized by the liver. WAKIX is contraindicated in patients with severe hepatic impairment. Dosage adjustment is required in patients with moderate hepatic impairment.

WAKIX is not recommended in patients with end-stage renal disease. Dosage adjustment of WAKIX is recommended in patients with moderate or severe renal impairment. 

Dosage reduction is recommended in patients known to be poor CYP2D6 metabolizers; these patients have higher concentrations of WAKIX than normal CYP2D6 metabolizers.

Please see the Full Prescribing Information for WAKIX for more information.

To report suspected adverse reactions, contact Harmony Biosciences at 1-800-833-7460 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

About Harmony
Biosciences

Harmony Biosciences is a commercial stage pharmaceutical company headquartered in Plymouth Meeting, PA and Chicago, IL. The company was established by Paragon Biosciences, LLC, and is focused on providing novel treatment options for people living with rare, neurological disorders who have unmet medical needs. For more information on Harmony Biosciences, please visit the company’s website: www.harmonybiosciences.com.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our product WAKIX®. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our commercialization efforts and strategy for WAKIX®; the rate and degree of market acceptance and clinical utility of WAKIX®, pitolisant in additional indications, if approved, and any other product candidates we may develop or acquire, if approved; our research and development plans, including our plans to explore the therapeutic potential of pitolisant in additional indications; our ongoing and planned clinical trials; our ability to expand the scope of our license agreement with
Bioprojet
; the availability of favorable insurance coverage and reimbursement for WAKIX®; the impact of the COVID-19 pandemic; the timing of and our ability to obtain regulatory approvals for pitolisant for other indications as well as any other product candidates; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; our commercialization, marketing and manufacturing capabilities and strategy; significant competition in our industry; our intellectual
property position; loss or retirement of key members of management; failure to successfully execute our growth strategy, including any delays in our planned future growth; our failure to maintain effective internal controls; the impact of government laws and regulations; volatility and fluctuations in the price of our common stock; and the significant costs and required management time as a result of operating as a public company; the fact that the price of the company’s common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in our
Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission (the “SEC”)
on
November 12
, 2020, and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

HARMONY BIOSCIENCES HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED

STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME (LOSS)

(In thousands except share and per share data)

  Three Months Ended September 30, Nine Months Ended September 30,
  2020 2019 2020 2019
Net product revenues $ 45,609   $   $ 103,454   $  
Cost of product sold   7,890         17,820      
Gross profit   37,719         85,634      
Operating expenses:        
Research and development   4,230     4,336     11,829     62,319  
Sales and marketing   12,601     12,908     38,297     27,477  
General and administrative   10,508     12,560     26,280     22,415  
Total operating expenses   27,339     29,804     76,406     112,211  
Operating income (loss)   10,380     (29,804 )   9,228     (112,211 )
Loss on debt extinguishment           (22,639 )    
Other expense, net   (1,525 )       (3,071 )    
Interest expense, net   (6,946 )   (2,095 )   (20,254 )   (3,326 )
Income (loss) before income taxes   1,909     (31,899 )   (36,736 )   (115,537 )
Income taxes                
Net income (loss) and comprehensive loss $ 1,909   $ (31,899 ) $ (36,736 ) $ (115,537 )
Accumulation of dividends on preferred stock   (6,013 )   (9,027 )   (26,904 )   (25,656 )
Net loss available to common stockholders $ (4,104 ) $ (40,926 ) $ (63,640 ) $ (141,193 )
NET LOSS PER SHARE:        
Basic $ (0.14 ) $ (5.26 ) $ (4.15 ) $ (18.15 )
Diluted $ (0.14 ) $ (5.26 ) $ (4.15 ) $ (18.15 )
Weighted average number of shares of common stock – basic   30,212,959     7,777,100     15,324,362     7,777,100  
Weighted average number of shares of common stock – diluted   30,212,959     7,777,100     15,324,362     7,777,100  
         

HARMONY BIOSCIENCES HOLDINGS, INC.

UNAUDITED CONDENSED CONSO
LIDATED BALANCE SHEETS
(In thousands except share and per share data)

  September 30, 2020 December 31, 2019
ASSETS    
CURRENT ASSETS:    
Cash and cash equivalents $ 221,740   $ 24,457  
Trade receivables, net   16,326     4,255  
Inventory, net   2,311     1,088  
Prepaid expenses   4,240     1,436  
Other current assets   5,625     261  
Total current assets   250,242     31,497  
NONCURRENT ASSETS:    
Property and equipment, net   1,038     1,330  
Restricted cash   750     750  
Intangible asset, net   66,625     72,185  
Other noncurrent assets   1,418     941  
Total noncurrent assets   69,831     75,206  
TOTAL ASSETS $ 320,073   $ 106,703  
LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS’ EQUITY (DEFICIT)    
CURRENT LIABILITIES:    
Trade payables $ 9,347   $ 6,360  
Accrued compensation   5,243     7,917  
Accrued expenses   17,200     5,500  
Other current liabilities       115  
Total current liabilities   31,790     19,892  
NONCURRENT LIABILITIES:    
Deferred rent   305     287  
Long term debt, net   192,858     97,946  
Other noncurrent liabilities   571     163  
Total noncurrent liabilities   193,734     98,396  
TOTAL LIABILITIES   225,524     118,288  
COMMITMENTS AND CONTINGENCIES (Note 9)    
CONVERTIBLE PREFERRED STOCK    
Convertible preferred stock, net of placement costs    
Series A convertible preferred stock – $1.00 stated value; 0 shares and 286,000,000 shares authorized at September 30, 2020 and December 31, 2019, respectively; 0 shares and 285,000,000 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively       348,203  
Series B convertible preferred stock – $1.25 stated value; 0 shares and 8,030,000 shares authorized at September 30, 2020 and December 31, 2019, respectively; 0 shares and 8,000,000 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively       12,023  
Series C convertible preferred stock – $1.96 stated value; 0 shares and 25,600,000 shares authorized at September 30, 2020 and December 31, 2019, respectively; 0 shares and 25,510,205 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively       51,051  
STOCKHOLDERS’ EQUITY (DEFICIT):        
Preferred stock – $0.00001 par value; 10,000,000 shares and 0 shares authorized at September 30, 2020 and December 31, 2019, respectively; 0 shares issued and outstanding at September 30, 2020 and December 31, 2019        
Common stock – $0.00001 par value; 500,000,000 shares and 423,630,000 shares authorized at September 30, 2020 and December 31, 2019, respectively; 56,888,625 shares and 7,787,470 issued and outstanding at September 30, 2020 and December 31, 2019, respectively   1      
Additional paid in capital   582,535      
Accumulated deficit   (487,987 )   (422,862 )
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)   94,549     (422,862 )
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS’ EQUITY (DEFICIT) $ 320,073   $ 106,703  
     

Harmony Biosciences Investor Contact:

Lisa Caperelli
610-608-0215
[email protected]

Harmony Biosciences Media Contact:

Nancy Leone
215-891-6046
[email protected]

Aligos Therapeutics is awarded €1.8M VLAIO grant to advance chronic hepatitis B research

SOUTH SAN FRANCISCO, Calif. and LEUVEN, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that its Belgian subsidiary Aligos Belgium BV has been awarded a €1.8M grant by the Flemish Agency for Innovation and Entrepreneurship (VLAIO) to support a nonclinical research project related to combination therapy for Hepatitis B at Aligos (CoHeBA).

“CoHeBA aims to elucidate the mechanism of action of the therapeutic candidates for chronic hepatitis B (CHB) currently in development at Aligos,” said Yannick Debing, Ph.D., principal scientist and lead on the project application. “The support from VLAIO will allow us to collaborate with some of the most esteemed leaders in the hepatitis B field to identify how Aligos’ CHB assets target components of the hepatitis B virus life cycle. Developing a greater understanding of the candidates’ mechanism of action will empower our scientific team to develop pharmacologically best-in-class therapies.”

The three-year project will include collaborations with the laboratories of Prof. Jan Paeshuyse (KU Leuven, Belgium), Profs. Stephen Locarnini and Hans Netter (VIDRL, Melbourne, Australia), Profs. Patrick Kennedy and Upkar Gill (Queen Mary University London, United Kingdom), and Profs. Thomas Baumert and Eloi Verrier (INSERM U1110, University of Strasbourg, France).

“Our team at Aligos Belgium BV contributes greatly to our success in discovering potential therapies for an infection that affects hundreds of millions of people, increasing their risk of end-stage liver disease,” said Lawrence Blatt, Ph.D., MBA, Chief Executive Officer of Aligos. “We expect that the outcomes of this project will help us design the most promising combination therapies and next-generation therapeutics for those patients.”

About Chronic Hepatitis B (CHB)

CHB is a major cause of chronic liver disease that affects over 290 million people worldwide. Serious complications of CHB include cirrhosis and liver cancer, which are associated with significant mortality. Approximately 900,000 people died from CHB-related causes in 2015 alone and the mortality rate associated with HBV-related liver cancer continues to increase. Although current standard of care for patients with CHB is effective in suppressing HBV, it is associated with very low rates of functional cure, which is the goal for future CHB treatments.

About Aligos

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

About the Agency for Innovation & Entrepreneurship

(
Agentschap
Innoveren
&
Ondernemen
, VLAIO) – www.vlaio.be

This project is supported by the Agency for Innovation & Entrepreneurship, the point of contact of the Flemish Government for all entrepreneurs in Flanders. VLAIO stimulates and supports innovation and entrepreneurship and contributes to a favorable entrepreneurial climate, in collaboration with many partners.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding Aligos’s expectations that the outcomes of the CoHebA project will enable Aligos’ development of next generation, pharmacologically best-in-class therapies and Aligos’ design of combination therapies. Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos’s clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’s prospectus filed with the Securities and Exchange Commission on October 19, 2020, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Media Contact

Amy Jobe, Ph.D.
LifeSci Communications
+1 315 879 8192
[email protected]

Investor Contact

Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
[email protected]

 

Williams Reports Third Quarter 2020 Financial Results

Revenue $66.2 Million; Gross Margin 13.1%

ATLANTA, Nov. 12, 2020 (GLOBE NEWSWIRE) — Williams Industrial Services Group Inc. (OTCQX: WLMS) (“Williams” or the “Company”), a construction and maintenance services company, today reported its financial results for the fiscal third quarter ended September 30, 2020.

Recent Highlights

  • Williams posted revenue of $66.2 million for the third quarter of 2020 compared with $56.9 million in the prior-year period
  • The Company reported net income of $1.0 million, or $0.04 per share, in the third quarter of 2020 versus a net loss of $0.3 million, or $(0.02) per share, in the third quarter of 2019
  • Adjusted EBITDA1 was $4.0 million for the third quarter of 2020 compared with $1.8 million in the third quarter of 2019
  • As of September 30, 2020, the Company’s backlog was $457.9 million compared to $494.9 million as of December 31, 2019 and $538.9 million as of June 30, 2020, with approximately $166.7 million expected to be converted to revenue over the next twelve months
  • Williams generated $3.2 million of operating cash in the third quarter of 2020 and reduced debt by $3.2 million concurrently
  • Williams is in the final stages of refinancing its debt, which it expects to be completed in the fourth quarter

“The third quarter of 2020 once again illustrated the strength and resilience of our business during a tumultuous year,” said Tracy Pagliara, President and CEO of Williams. “The Company posted revenue of $66.2 million, up 16.5%, expanded gross margins by 260 basis points, to 13.1%, and generated $0.04 earnings per share versus a loss of $(0.02) per share, on a year-over-year basis. We ended the quarter with a backlog of $457.9 million.

“Such performance reinforces our confidence in the Company’s strategic plan as we also strive to complete the refinancing of our credit facilities. We have advanced that project significantly over the past two months and feel optimistic it will be finalized during the fourth quarter, setting the stage for reduced interest expense heading into 2021. At the same time, we are continuing to pursue our growth initiatives by building our talent base and enhancing internal controls and processes, while also remaining focused on leveraging SG&A. Such actions – combined with anticipated lower interest costs and our solid backlog and pipeline – represent exciting progress as we near the end of an extraordinary year and look forward to a further improved 2021.”


See NOTE 1 — Non-GAAP Financial Measures in the attached tables for important disclosures regarding Williams’ use of Adjusted EBITDA, as well as a reconciliation of income (loss) from continuing operations to adjusted EBITDA. 

Third Quarter 2020 Financial Results Compared to Third Quarter 2019

Revenue in the third quarter of 2020 was $66.2 million compared with $56.9 million in the third quarter of fiscal 2019, reflecting $3.3 million of higher revenue from Canadian nuclear contracts, a $5.0 million increase related to fuel storage/decommissioning work, and $0.6 million of additional revenue from the Vogtle 3 & 4 nuclear construction project.

Gross profit was $8.7 million, or 13.1% of revenue, compared with $6.0 million, or 10.5% of revenue, in the prior-year period. The current year gross margin reflects $2.4 million for prior-year unfavorable adjustments related to a customer contract. Operating expenses were $6.0 million versus $5.2 million in the third quarter of 2019, reflecting higher general and administrative (G&A) costs due primarily to a $0.8 million increase in severance and stock-based compensation expense. The Company’s operating margin rose to 4.0% from 1.3% in the prior-year third quarter, reflecting the improvement in gross margin year-over-year. Interest expense was $1.5 million in the third quarter of both fiscal 2020 and 2019.

The Company reported net income of $1.0 million, or $0.04 per share, in the third quarter of 2020 compared with a net loss of $0.3 million, or $(0.02) per share, in the prior-year period.

Balance Sheet

As of September 30, 2020, the Company had $4.5 million of cash (including restricted cash) and $41.5 million of bank debt compared with $7.8 million of cash and $44.2 million of bank debt as of December 31, 2019. Debt was reduced by $3.2 million in the third quarter, and further reductions are anticipated going forward as the Company utilizes cash generation to lower indebtedness.

Backlog

Total backlog as of September 30, 2020 was $457.9 million compared with $494.9 million at December 31, 2019 and $538.9 million as of June 30, 2020. The Company recognized revenue of $66.2 million in the third quarter combined with net adjustments and cancellations of $26.9 million, which were primarily driven by scope reduction and revision to the completion date on a particular contract. Revenue recognized and net adjustments and cancellations were partially offset with new awards of $12.2 million. 

             
(in thousands)   Three Months Ended September 30, 2020   Nine Months Ended September 30, 2020
Backlog – beginning of period   $ 538,860     $ 494,904  
New awards     12,235       146,651  
Adjustments and cancellations, net     (26,923 )     21,313  
Revenue recognized     (66,240 )     (204,936 )
Backlog – end of period   $ 457,932     $ 457,932  

Williams estimates that approximately $166.7 million, or 36.4%, of total backlog will be converted to revenue in the next twelve months. This compares with $191.3 million of backlog at December 31, 2019 and $211.2 million of backlog at June 30, 2020 that the Company anticipated would be converted to revenue over the succeeding twelve-month period.

Outlook

The Company reaffirmed previously-issued guidance for fiscal 2020.

   
2020 Guidance  
Revenue: $270 million to $290 million
Gross margin: 11% to 13% of revenue
SG&A: 8% to 8.5% of revenue
Adjusted EBITDA*: $13 million to $15 million

*See Note 1—Non-GAAP Financial Measures for information regarding the use of Adjusted EBITDA and forward-looking non-GAAP financial measures.

Webcast and Teleconference

The Company will host a conference call today, November 12, 2020, at 10:00 a.m. Eastern time. A webcast of the call and an accompanying slide presentation will be available at www.wisgrp.com. To access the conference call by telephone, listeners should dial 201-493-6780.

An audio replay of the call will be available later that day by dialing 412-317-6671 and entering conference ID number 13711774. Alternatively, you may access the webcast replay at http://ir.wisgrp.com/, where a transcript will be posted once available.

About Williams

Williams Industrial Services Group has been safely helping plant owners and operators enhance asset value for more than 50 years. The Company provides a broad range of construction, maintenance and modification, and support services to customers in energy and industrial end markets. Williams’ mission is to be the preferred provider of construction, maintenance, and specialty services through commitment to superior safety performance, focus on innovation, and dedication to delivering unsurpassed value to its customers.

Additional information about Williams can be found on its website: www.wisgrp.com.

Forward-looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the term set forth in the Private Securities Litigation Reform Act of 1995. The forward-looking statements include statements or expectations regarding the Company’s ability to perform in accordance with guidance, realize opportunities and successfully achieve its growth and strategic initiatives, the impact of the COVID-19 pandemic on the Company’s business, operations, and financial condition, the Company’s ability to control costs, future demand for the Company’s services, the Company’s ability to manage overhead, streamline operations, improve backlog, performance and cash flow, and deleverage the balance sheet, expectations regarding future contract awards and positive cash flow, the Company’s ability to complete the refinancing of its outstanding debt in the fourth quarter of 2020, and other related matters. These statements reflect the Company’s current views of future events and financial performance and are subject to a number of risks and uncertainties, some of which have been, and may further be, exacerbated by the COVID-19 pandemic, including its ability to comply with the terms of its debt instruments and access letters of credit, ability to implement strategic initiatives, business plans, and liquidity plans, and ability to maintain effective internal control over financial reporting and disclosure controls and procedures. Actual results, performance or achievements may differ materially from those expressed or implied in the forward-looking statements. Additional risks and uncertainties that could cause or contribute to such material differences include, but are not limited to, the Company’s level of indebtedness; the Company’s ability to make interest and principal payments on its debt and satisfy the financial and other covenants contained in its credit facilities; the Company’s ability to engage in certain transactions and activities due to limitations and covenants contained in its credit facilities; the Company’s ability to enter into new lending facilities, if needed, and to obtain adequate surety bonding and letters of credit; the Company’s ability to generate sufficient cash resources to continue funding operations, including investments in working capital required to support growth-related commitments that it makes to its customers, and the possibility that the Company incurs losses from operations in the future; exposure to market risks from changes in interest rates, including changes to or replacement of LIBOR; the possibility the Company may be required to write-down additional amounts of goodwill and other indefinite-lived assets; failure to maintain effective internal control over financial reporting and disclosure controls and procedures in the future; changes in the Company’s senior management and financial reporting and accounting teams, the ability of such persons to successfully perform their roles, and the Company’s ability to attract and retain qualified personnel, skilled workers and key officers; a failure to successfully implement or realize the Company’s business strategies, plans and objectives of management, and liquidity, operating and growth initiatives and opportunities; the loss of one or more of the Company’s significant customers; the Company’s competitive position; market outlook and trends in the Company’s industry, including the possibility of reduced investment in, or increased regulation of, nuclear power plants and declines in public infrastructure construction and reductions in government funding, including funding by state and local agencies; costs exceeding estimates the Company uses to set fixed-price contracts; harm to the Company’s reputation or profitability due to, among other things, internal operational issues, poor subcontractor performances or subcontractor insolvency; potential insolvency or financial distress of third parties, including the Company’s customers and suppliers; the Company’s contract backlog and related amounts to be recognized as revenue; the Company’s ability to maintain its safety record, the inherently dangerous nature of the services it provides, the risks of potential liability and adequacy of insurance; changes in the Company’s credit profile and market conditions affecting its relationships with suppliers, vendors and subcontractors; compliance with environmental, health, safety and other related laws and regulations; expiration of the Price-Anderson Act’s indemnification authority; the Company’s expected financial condition, future cash flows, results of operations and future capital and other expenditures; the impact of general economic conditions, including the current economic disruption and recession in the U.S. resulting from the COVID-19 pandemic; the impact of the COVID‑19 pandemic on revenues, expenses, uncollectible accounts, capital investment programs, cash flows, liquidity, maintenance of existing assets, and other operating expenses; the potential for additional COVID-19 cases to occur at the Company’s active or future job sites, as has occurred at the Plant Vogtle site in Georgia, during the COVID-19 pandemic, which potentially could impact cost and labor availability; information technology vulnerabilities and cyberattacks on the Company’s networks; the Company’s failure to comply with applicable laws and regulations, including, but not limited to, those relating to privacy and anti-bribery; the Company’s participation in multiemployer pension plans; the impact of any disruptions resulting from the expiration of collective bargaining agreements; availability of raw materials and inventories; the impact of natural disasters and other severe catastrophic events (such as the ongoing COVID-19 pandemic); future income tax payments and utilization of net operating loss and foreign tax credit carryforwards, including any impact relating to the Tax Cuts and Jobs Act of 2017, the CARES Act or other tax changes; future compliance with orders of and agreements with regulatory agencies; volatility of the market price for the Company’s common stock and stockholders’ ability to resell their shares of the Company’s common stock; the Company’s ability to pay cash dividends in the future; the impact of future offerings or sales of the Company’s common stock on the market price of such stock; expected outcomes of legal or regulatory proceedings and their expected effects on the Company’s results of operations, including future liabilities, fees and expenses resulting from the Koontz-Wagner bankruptcy filing; and any other statements regarding future growth, future cash needs, future operations, business plans and future financial results.

Other important factors that may cause actual results to differ materially from those expressed in the forward-looking statements are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including the sections of the Annual Report on Form 10-K for its 2019 fiscal year and subsequently filed Quarterly Reports on Form 10-Q titled “Risk Factors.” Any forward-looking statement speaks only as of the date of this press release. Except as may be required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and you are cautioned not to rely upon them unduly.

Investor Contact:

Chris Witty
Darrow Associates
646-345-0998
[email protected]

Financial Tables Follow

WILLIAMS INDUSTRIAL SERVICES GROUP INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
                         
    Three Months Ended September 30,   Nine Months Ended September 30,
($ in thousands, except share and per share amounts)   2020
  2019
  2020
  2019
Revenue   $ 66,240     $ 56,862     $ 204,936     $ 178,980  
Cost of revenue     57,582       50,906       180,014       157,150  
                         
Gross profit     8,658       5,956       24,922       21,830  
Gross margin     13.1%       10.5%       12.2%       12.2%  
                         
Selling and marketing expenses     123       63       401       468  
General and administrative expenses     5,827       5,091       17,413       16,327  
Depreciation and amortization expense     46       77       144       225  
Total operating expenses     5,996       5,231       17,958       17,020  
                         
Operating income     2,662       725       6,964       4,810  
Operating margin     4.0%       1.3%       3.4%       2.7%  
                         
Interest expense, net     1,541       1,511       4,640       4,504  
Other income, net     (316 )     (485 )     (937 )     (1,153 )
Total other expenses, net     1,225       1,026       3,703       3,351  
                         
Income (loss) from continuing operations before income tax     1,437       (301 )     3,261       1,459  
Income tax expense     321       62       565       141  
Income (loss) from continuing operations     1,116       (363 )     2,696       1,318  
                         
Loss from discontinued operations before income tax     (66 )     (54 )     (222 )     (175 )
Income tax expense (benefit)     24       (97 )     (56 )     (845 )
Income (loss) from discontinued operations     (90 )     43       (166 )     670  
                         
Net income (loss)   $ 1,026     $ (320 )   $ 2,530     $ 1,988  
                         
Basic earnings (loss) per common share                        
Income (loss) from continuing operations   $ 0.04     $ (0.02 )   $ 0.12     $ 0.07  
Income (loss) from discontinued operations     (0.00 )     0.00       (0.01 )     0.04  
Basic earnings (loss) per common share   $ 0.04     $ (0.02 )   $ 0.11     $ 0.11  
                         
Diluted earnings (loss) per common share                        
Income (loss) from continuing operations   $ 0.04     $ (0.02 )   $ 0.11     $ 0.07  
Income (loss) from discontinued operations     (0.00 )     0.00       (0.00 )     0.03  
Diluted earnings (loss) per common share   $ 0.04     $ (0.02 )   $ 0.11     $ 0.10  
                         
Weighted average common shares outstanding (basic)     24,689,337       18,732,402       23,304,059       18,653,301  
Weighted average common shares outstanding (diluted)     25,184,306       18,732,402       23,836,798       18,976,619  

WILLIAMS INDUSTRIAL SERVICES GROUP INC. AND SUBSIDIARIES

REVENUE BRIDGE ANALYSIS*

Third Quarter 2020 Revenue Bridge

       
(in millions)     $ Change
Third quarter 2019 revenue   $ 56.9
Plant Vogtle Units 3 and 4     0.6
Canada     3.3
Decommissioning     5.0
Project mix     0.4
Total change     9.3
Third quarter 2020 revenue*   $ 66.2

*Numbers may not sum due to rounding

WILLIAMS INDUSTRIAL SERVICES GROUP INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
             
    September 30,   December 31,
($ in thousands, except share and per share amounts)   2020
  2019
ASSETS            
Current assets:            
Cash and cash equivalents   $ 3,998     $ 7,350  
Restricted cash     468       468  
Accounts receivable, net of allowance of $358 and $377, respectively     44,682       38,218  
Contract assets     8,795       7,225  
Other current assets     6,169       2,483  
Total current assets     64,112       55,744  
             
Property, plant and equipment, net     355       273  
Goodwill     35,400       35,400  
Intangible assets     12,500       12,500  
Other long-term assets     6,648       8,549  
Total assets   $ 119,015     $ 112,466  
             
LIABILITIES AND STOCKHOLDERS’ EQUITY            
             
Current liabilities:            
Accounts payable   $ 7,615     $ 16,618  
Accrued compensation and benefits     16,680       9,318  
Contract liabilities     3,405       2,699  
Short-term borrowings     8,307       10,849  
Current portion of long-term debt     700       700  
Other current liabilities     8,435       6,408  
Current liabilities of discontinued operations     339       340  
Total current liabilities     45,481       46,932  
Long-term debt, net     32,462       32,658  
Deferred tax liabilities     2,253       2,198  
Other long-term liabilities     2,272       4,028  
Long-term liabilities of discontinued operations     4,464       4,486  
Total liabilities     86,932       90,302  
Commitments and contingencies            
Stockholders’ equity:            
Common stock, $0.01 par value, 170,000,000 shares authorized, and 25,926,333 and 19,794,270 shares issued, respectively, and 25,336,442 and 19,057,195 shares outstanding, respectively     256       198  
Paid-in capital     89,582       81,964  
Accumulated other comprehensive income (loss)     (66 )     222  
Accumulated deficit     (57,681 )     (60,211 )
Treasury stock, at par (589,891 and 737,075 common shares, respectively)     (8 )     (9 )
Total stockholders’ equity     32,083       22,164  
Total liabilities and stockholders’ equity   $ 119,015     $ 112,466  

WILLIAMS INDUSTRIAL SERVICES GROUP INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
             
    Nine Months Ended September 30,
(in thousands)   2020
  2019
Operating activities:            
Net income   $ 2,530     $ 1,988  
Adjustments to reconcile net income to net cash used in operating activities:            
Net income (loss) from discontinued operations     166       (670 )
Deferred income tax provision (benefit)     55       (68 )
Depreciation and amortization on plant, property and equipment     144       225  
Amortization of deferred financing costs     546       462  
Gain on disposals of property, plant and equipment     (136 )      
Bad debt expense     19       53  
Stock-based compensation     1,703       1,114  
Changes in operating assets and liabilities, net of businesses acquired and sold:            
Accounts receivable     (6,530 )     (7,843 )
Contract assets     (1,553 )     (4,159 )
Other current assets     (3,684 )     (1,918 )
Other assets     1,619       1,404  
Accounts payable     (8,914 )     8,016  
Accrued and other liabilities     7,290       (2,705 )
Contract liabilities     706       2,039  
Net cash used in operating activities, continuing operations     (6,039 )     (2,062 )
Net cash used in operating activities, discontinued operations     (189 )     (350 )
Net cash used in operating activities     (6,228 )     (2,412 )
Investing activities:            
Purchase of property, plant and equipment     (88 )     (178 )
Net cash used in investing activities, continuing operations     (88 )     (178 )
Financing activities:            
Repurchase of stock-based awards for payment of statutory taxes due on stock-based compensation     (227 )     (154 )
Proceeds from issuance of common stock     6,488        
Debt issuance costs     (325 )      
Proceeds from short-term borrowings     172,616       163,040  
Repayments of short-term borrowings     (175,158 )     (162,416 )
Repayments of long-term debt     (350 )     (350 )
Net cash provided by financing activities, continuing operations     3,044       120  
Effect of exchange rate change on cash, continuing operations     (80 )      
Net change in cash, cash equivalents and restricted cash     (3,352 )     (2,470 )
Cash, cash equivalents and restricted cash, beginning of period     7,818       4,942  
Cash, cash equivalents and restricted cash, end of period   $ 4,466     $ 2,472  
             
Supplemental Disclosures:            
Cash paid for interest   $ 2,900     $ 3,527  
Noncash amendment fee related to MidCap Facility   $ 150     $  

WILLIAMS INDUSTRIAL SERVICES GROUP INC. AND SUBSIDIARIES

NON-GAAP FINANCIAL MEASURE (UNAUDITED)

This press release contains financial measures not derived in accordance with accounting principles generally accepted in the United States (“GAAP”). A reconciliation to the most comparable GAAP measure is provided below.

ADJUSTED EBITDA-CONTINUING OPERATIONS

                         
    Three Months Ended September 30,   Nine Months Ended September 30,
(in thousands)   2020
  2019
  2020
  2019
Net income   $ 1,026     $ (363 )   $ 2,530     $ 1,318  
Add back:                        
Interest expense, net     1,541       1,511       4,640       4,504  
Income tax expense     321       62       565       141  
Depreciation and amortization expense     46       77       144       225  
Stock-based compensation     614       120       1,702       1,011  
Severance costs     421       125       421       449  
Other professional fees     38             263        
Franchise taxes     64       64       203       192  
Loss on other receivables                       189  
Consulting expenses-remediation           152             152  
Settlement expenses                 129        
Foreign currency loss (gain)     (83 )     (27 )     (24 )     (186 )
Restructuring charges           116             137  
Other non-recurring expenses                       241  
Adjusted EBITDA   $ 3,988     $ 1,837     $ 10,573     $ 8,373  

NOTE 1 — Non-GAAP Financial Measures


Adjusted EBITDA

Adjusted EBITDA is not calculated through the application of GAAP and is not the required form of disclosure by the U.S. Securities and Exchange Commission. Adjusted EBITDA is the sum of our net income (loss) before interest expense, net, and income tax (benefit) expense and unusual gains or charges. It also excludes non-cash charges such as depreciation and amortization. The Company’s management believes adjusted EBITDA is an important measure of operating performance because it allows management, investors and others to evaluate and compare the performance of its core operations from period to period by removing the impact of the capital structure (interest), tangible and intangible asset base (depreciation and amortization), taxes and unusual gains or charges (stock-based compensation, severance costs, other estimated non-recurring expenses, franchise taxes, consulting expenses, bank restructuring costs, foreign currency gain, restructuring charges, asset disposition charges and restatement expenses), which are not always commensurate with the reporting period in which such items are included. Williams’ credit facility also contains ratios based on EBITDA. Adjusted EBITDA should not be considered an alternative to net income or as a better measure of liquidity than net cash flows from operating activities, as determined by GAAP, and, therefore, should not be used in isolation from, but in conjunction with, the GAAP measures. The use of any non-GAAP measure may produce results that vary from the GAAP measure and may not be comparable to a similarly defined non-GAAP measure used by other companies.


Note Regarding Forward-Looking Non-GAAP Financial Measures


The Company does not provide a reconciliation of forward-looking non-GAAP financial measures to their comparable GAAP financial measures because it could not do so without unreasonable effort due to the unavailability of the information needed to calculate reconciling items and due to the variability, complexity and limited visibility of the adjusting items that would be excluded from the non-GAAP financial measures in future periods. When planning, forecasting and analyzing future periods, the Company does so primarily on a non-GAAP basis without preparing a GAAP analysis.